Table 2. Primary and Key Secondary Outcomes: Effect of Zinc vs Placebo on Markers of Mortality, HIV Progression, Cardiovascular Disease Risk and Inflammation.
| Marker | Zinc group (n = 126) | Placebo group (n = 128) | Adjusted mean difference (95% CI) | P value |
|---|---|---|---|---|
| Change from baseline to 18 mo | ||||
| Veterans Aging Cohort Study Index score | ||||
| Mean (SD) | 0.49 (14.6) | 5.5 (17.2) | −4.68 (−9.62 to 0.25) | .06 |
| Median (IQR) | 0 (−7.0 to 6.0) | 6.0 (−6.0 to 14.0) | ||
| CD4 cell count, cells/mm3 | ||||
| Mean (SD) | −128.8 (232.9) | −176.2 (220.6) | 41.8 (−20.3 to 103.8) | .19 |
| Median (IQR) | −116.9 (−242.3 to 39.9) | −135.6 (−283.9 to −48.6) | ||
| At 18 mo | ||||
| Reynolds Risk Scorea | ||||
| Mean (SD) | −0.17 (0.8) | −0.19 (0.9) | −0.014 (−0.167 to 0.139) | .85 |
| Median (IQR) | 0.17 (−0.75 to 0.38) | −0.14 (−0.95 to 0.55) | ||
| Interleukin-6, pg/mLa | ||||
| Mean (SD) | −0.03 (0.9) | 0.17 (0.9) | −0.13 (−0.38 to 0.11) | .30 |
| Median (IQR) | −0.02 (−0.75 to 0.41) | 0.13 (−0.43 to 0.67) | ||
| Dimerized plasmin fragment D, μg/mL fibrinogen equivalent unitsa | ||||
| Mean (SD) | −0.94 (1.0) | −0.80 (1.0) | −0.21 (−0.48 to 0.07) | .14 |
| Median (IQR) | −0.97 (−1.56 to −0.27) | −0.84 (−1.43 to −0.14) | ||
| Soluble CD14, mean (SD), ng/mL | 2086.26 (445.7) | 2099.61 (491.8) | −38.01 (−166.90 to 90.88) | .56 |
| Intestinal fatty acid binding protein, mean (SD), pg/mLa | 7.19 (0.4) | 7.09 (0.5) | 0.08 (−0.07 to 0.22) | .32 |
| Lipopolysaccharide binding protein, mean (SD), ng/mLa | 8.07 (0.5) | 8.20 (0.5) | −0.09 (−0.23 to 0.06) | .24 |
Abbreviation: IQR, interquartile range.
SI conversion factor: To convert dimerized plasmin fragment D to nmol/L, multiply by 5.476.
a
Natural log-transformation.